Public Advisory - Unauthorized blood glucose monitors sold online may pose serious health risks Français
Product: Unauthorized blood glucose monitors, also referred to as glucose-reading devices or non-invasive glucose monitors
Issue: Health products - Unauthorized product; Medical devices - Inaccurate test or measurement results
What to do: Do not use glucose monitors that have not been authorized by Health Canada. Consult a healthcare professional if you have used an unauthorized glucose monitor and have health concerns. Only use devices listed on Health Canada's Medical Device Active Licence Listing (MDALL).
Issue
Health Canada is warning people with diabetes and their caregivers that numerous unauthorized blood glucose monitors are being sold through social media and online stores.
Unauthorized products have not been assessed for safety and effectiveness and may pose serious health risks to consumers because they may give false blood glucose readings or may not provide timely alerts, which could lead to errors in diabetes management. Errors may include:
taking too little insulin, which can lead to high blood sugar (called hyperglycemia),
taking too much insulin, which can lead to low blood sugar (called hypoglycemia), and
failing to treat low or high blood sugar.
These errors could lead to serious health consequences requiring medical treatment, such as hyperglycemic emergencies, severely low blood sugar, loss of consciousness, seizures, coma, and death.
These unauthorized devices are being marketed using various descriptions, including glucose-reading devices, blood glucose monitoring systems, non-invasive glucose/health monitors, non-invasive blood glucose meters/monitors, and glucose and vital signs monitors.
While some of these unauthorized devices claim to measure glucose levels non-invasively (without puncturing the skin or inserting a device into the body), consumers should be aware that at this time, Health Canada has not authorized the sale of any non-invasive blood glucose monitoring devices.
In addition, some of the promotional material for these unauthorized products contain false endorsements from Health Canada using its corporate signature. Health Canada does not endorse health products and does not allow its corporate signature to appear on health or consumer product advertising.
Consumers can search Health Canada's Medical Device Active Licence Listing (MDALL) to determine whether a blood glucose monitor has been authorized by the department.
Health Canada will continue to take necessary action to stop the sale and advertising of these unauthorized products in Canada.
What you should do
Only use blood glucose monitors that have been authorized by Health Canada.
If you suspect that you are using an unauthorized product, stop using it immediately and replace it with an authorized monitor.
Talk to your health care provider about which blood glucose monitor is right for you.
Only use devices listed on Health Canada's Medical Device Active Licence Listing (MDALL).
Report any health product-related side effects or complaints to Health Canada.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
21 hours ago
- CTV News
CTV National News: How the measles are spreading across Canada
Watch Prince Edward Island is the latest province to report two possible cases of measles as the busy summer travel season gets underway. John Vennavally-Rao reports.
Cision Canada
a day ago
- Cision Canada
Health Canada launches public consultation on proposed changes to increase oversight of precursor chemicals and drug equipment
OTTAWA, ON, June 27, 2025 /CNW/ - The Government of Canada is taking action to keep communities safe on both sides of the border. This includes detecting and disrupting the illegal fentanyl trade. Today, the Minister of Health, Marjorie Michel, launched a 45-day public consultation on proposed changes to how Canada regulates precursor chemicals and devices such as pill presses and encapsulators that could be used in the illegal production of drugs. The consultation is open until August 12, 2025. The public consultation will allow impacted stakeholders, such as regulated industries that use precursors for legitimate uses, pharmacies and individual pharmacists, to provide feedback on the proposed changes. These changes would strengthen controls around precursor chemicals and drug equipment to support law and border enforcement as they take action to stop their illegal importation and distribution. Quotes "Our government is acting to protect Canadians against illegal synthetic drugs like fentanyl. By working with the industry and our partners, we are making our streets safer." The Honourable Marjorie Michel Minister of Health "Keeping communities safe from the harms of illegal drugs is a top priority. Together with our Strong Borders bill, these proposed changes will give law enforcement and border officers stronger tools to stop the illegal production and trafficking of dangerous substances like fentanyl. We are committed to working with our partners to disrupt organized crime, further secure our borders and protect Canadians." The Honourable Gary Anandasangaree Minister of Public Safety "Step by step we are increasing pressure on organized crime groups and sending a clear message: Canada will not tolerate illegal drugs in our communities and at our borders. We will use every tool at our disposal to support law and border enforcement as they tackle the production and distribution of illegal drugs." Kevin Brosseau Fentanyl Czar Quick Facts Under the Controlled Drugs and Substances Act (CDSA), the Precursor Control Regulations (PCR) sets rules for the use of precursor chemicals. While some precursors have legitimate uses, they can also be used in the illegal production of controlled substances, like fentanyl and fentanyl analogues. In Canada, precursors are controlled under Schedule VI of the CDSA and are regulated under the PCR. To ensure that law and border enforcement have the tools they need to detect and address fentanyl and its precursors, the federal government is investing $78.7 million to expand Health Canada's laboratory and regulatory capabilities. Health Canada's Precursor Chemical Risk Management Unit provides better oversight into precursor chemicals and their distribution channels, and enhance monitoring and surveillance of illegal drug trends to enable timely law enforcement action. Health Canada is establishing a new Canadian Drug Analysis Centre that will allow for more specialized analysis of synthetic drug samples. The analysis will help determine how and where these substances were manufactured to support law enforcement and public safety partners to strategically target organized crime. Notice of Intent on this regulatory proposal to enhance oversight of precursor chemicals and drug equipment was open for public consultation from January 31 to March 3, 2025. 1S7Oa6kfqPnSMg%3D&rese SOURCE Health Canada (HC)
Cision Canada
a day ago
- Cision Canada
Public Advisory - Unauthorized blood glucose monitors sold online may pose serious health risks Français
Product: Unauthorized blood glucose monitors, also referred to as glucose-reading devices or non-invasive glucose monitors Issue: Health products - Unauthorized product; Medical devices - Inaccurate test or measurement results What to do: Do not use glucose monitors that have not been authorized by Health Canada. Consult a healthcare professional if you have used an unauthorized glucose monitor and have health concerns. Only use devices listed on Health Canada's Medical Device Active Licence Listing (MDALL). Issue Health Canada is warning people with diabetes and their caregivers that numerous unauthorized blood glucose monitors are being sold through social media and online stores. Unauthorized products have not been assessed for safety and effectiveness and may pose serious health risks to consumers because they may give false blood glucose readings or may not provide timely alerts, which could lead to errors in diabetes management. Errors may include: taking too little insulin, which can lead to high blood sugar (called hyperglycemia), taking too much insulin, which can lead to low blood sugar (called hypoglycemia), and failing to treat low or high blood sugar. These errors could lead to serious health consequences requiring medical treatment, such as hyperglycemic emergencies, severely low blood sugar, loss of consciousness, seizures, coma, and death. These unauthorized devices are being marketed using various descriptions, including glucose-reading devices, blood glucose monitoring systems, non-invasive glucose/health monitors, non-invasive blood glucose meters/monitors, and glucose and vital signs monitors. While some of these unauthorized devices claim to measure glucose levels non-invasively (without puncturing the skin or inserting a device into the body), consumers should be aware that at this time, Health Canada has not authorized the sale of any non-invasive blood glucose monitoring devices. In addition, some of the promotional material for these unauthorized products contain false endorsements from Health Canada using its corporate signature. Health Canada does not endorse health products and does not allow its corporate signature to appear on health or consumer product advertising. Consumers can search Health Canada's Medical Device Active Licence Listing (MDALL) to determine whether a blood glucose monitor has been authorized by the department. Health Canada will continue to take necessary action to stop the sale and advertising of these unauthorized products in Canada. What you should do Only use blood glucose monitors that have been authorized by Health Canada. If you suspect that you are using an unauthorized product, stop using it immediately and replace it with an authorized monitor. Talk to your health care provider about which blood glucose monitor is right for you. Only use devices listed on Health Canada's Medical Device Active Licence Listing (MDALL). Report any health product-related side effects or complaints to Health Canada.
